- Diabetes Prevention Program Saves People Money, Study Shows
- Despite Previous Data, Paxlovid May Be Useful for Long Covid After All
- Some GLP-1s Achieve More Weight Loss Than Others: Study
- More Evidence Bolsters the Oral Herpes and Alzheimer’s Link
- Health Advocates Are Unhappy with FDA Guidance on Lead Levels in Baby Food
- FDA Calls for Better Accuracy of Pulse Oximeters in People of Color
- Fluoride May Be Linked to Decreased IQ, Says “Limited Data,” Hard-to-Interpret Study
- First U.S. Death From Bird Flu Reported in Louisiana
- Blood Test May Help Predict How Long Immunity Lasts
- DoxyPEP Lowers Rate of Sexually Transmitted Infections (STIs), Data Suggests
Improved Artificial Heart Valve Approved
The newest version of the Sapien 3 Transcatheter Heart Valve has been approved by the U.S. Food and Drug Administration.
The artificial valve is designed for people with a narrowed aortic valve, a condition that restricts blood flow from the heart to the aorta, the body’s main artery. The product is sanctioned for people who are at high risk for death or serious complications from open-heart surgery to repair the narrowed valve, the FDA said in a news release.
The newly approved device is the third-generation Sapien 3, originally approved in 2011. The newest version includes changes designed to minimize leakage, the FDA said.
In people with aortic stenosis, the heart must work harder to pump blood through the narrowed opening. Symptoms can include fainting, chest pain, heart failure, irregular heartbeat and cardiac arrest.
Possible side effects of the device itself include stroke, serious kidney injury, heart attack, bleeding, the need for a pacemaker or death, the FDA said.
The device isn’t recommended for people who can’t tolerate anti-clotting therapy, the agency said.
The Sapien 3 is manufactured by Edwards Lifesciences, based in Irvine, Calif.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.